History
- 4–12 weeks after intraocular surgery (peak at 6 weeks) (cataract surgery/iris-claw [Artisan] lens implantation/vitrectomy, particularly in cases with complications)
- Decreased visual acuity, metamorphopsia
Differential diagnosis
- Side effect of topical prostaglandin analogues (e.g. Monoprost, Xalatan)
- wAMD, diabetic retinopathy, retinal vein occlusion
- Uveitis, epiretinal membrane, telangiectasia, vasculitis
Work-up
- RAPD
- Amsler grid (metamorphopsia, relative central scotomata)
- Subjective visual acuity
- Applanation tonometry and optic disc assessment
- Anterior segment (cells in the anterior chamber, vitreous incarceration, rubeosis iridis, IOL position)
- Fundus in mydriasis (vitreous cells, macular edema, flame-/blot-shaped hemorrhages, exudates, dilated/tortuous veins, disc swelling)
- OCT M P and photographs (macular edema in the INL/OPL, cells in the posterior vitreous, disc swelling)
- Fluorescein angiography if needed (late-phase leakage in the macular area, often also peripapillary)
Treatment
If findings are mild up to 4 weeks postoperatively with no cells in the anterior chamber > no treatment
If cells are additionally present in the anterior chamber > Pred Forte eye drops
- Prednisolone eye drops 4x/day (Pred Forte eye drops)
- Discontinue prostaglandin eye drops
- Topical NSAID for up to 6–12 weeks (Acular 4x/day, Yellox 2x/day, Nevanac 0.1% 3x/day, Nevanac 3mg/ml 1x/day)
- Follow-up after 2–4 weeks with OCT M P and photographs
If persistent
- Brinzolamide eye drops 2x/day (Azopt) (caution: contraindicated in severe renal insufficiency)
- Acetazolamide 250mg 3x/day (Diamox 250mg tablets) and potassium 1x/day (KCl effervescent tablet) (caution: contraindicated in severe renal insufficiency)
- Follow-up after 2–4 weeks with OCT M P and photographs
If further persistent
- Thorough examination in mydriasis (vitreous, IOL position, iris/pupil freely mobile, ultrasound if needed)
- Intravitreal steroids (Ozurdex)
- Obtain cost approval (insurance authorization)
- Duration of action 3–4 months
- Intravitreal anti-VEGF (Lucentis/Eylea) > indication: known steroid response
- Cost approval required (off-label use)
Prognosis
- Spontaneous resolution in 3–6 months
- Chronic course possible